LOS ANGELES / Jan 26, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference.
Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings throughout the event on Thursday, February 1, 2024.
To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. or register for the event at https://lythampartners.com/select2024invreg/.
For additional information on ChromaDex, visit www.chromadex.com, and for details on investor relations, please visit www.investors.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Last Trade: | US$3.80 |
Daily Change: | 0.02 0.53 |
Daily Volume: | 169,426 |
Market Cap: | US$288.530M |
September 10, 2024 August 07, 2024 July 23, 2024 July 16, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB